logo

RCEL

AVITA Medical·NASDAQ
--
--(--)
--
--(--)
9.97 / 10
Outperform

The company boasts superior fundamentals, highlighted by robust net cash flow from operating activities (36.96% YoY growth) and an interest coverage ratio of 15.48, indicating healthy earnings and low financial risk. However, inventory turnover is slow (206.4 days), and the quick ratio is only 0.55, suggesting liquidity constraints. Overall, the balance sheet is improving but working-capital management needs attention.

Fundamental(9.97)SentimentTechnical

Analysis Checks(7/10)

Total operating revenue (YoY growth rate %)
Value17.78
Score3/3
Weight675.62%
1M Return4.49%
Quick ratio
Value0.55
Score1/3
Weight-320.14%
1M Return-2.86%
Total profit (YoY growth rate %)
Value26.45
Score0/3
Weight-555.37%
1M Return-5.82%
Net cash flow from operating activities (YoY growth rate %)
Value36.96
Score2/3
Weight-71.67%
1M Return-0.70%
Fixed assets turnover ratio
Value4.06
Score2/3
Weight27.67%
1M Return0.24%
Long-term debt to working capital ratio (%)
Value27.19
Score0/3
Weight-447.60%
1M Return-4.72%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-184.62%
1M Return-1.71%
Operating revenue (YoY growth rate %)
Value17.78
Score3/3
Weight675.62%
1M Return4.49%
Net profit attributable to parent company shareholders (YoY growth rate %)
Value26.44
Score2/3
Weight317.15%
1M Return2.53%
Inventory turnover days
Value206.40
Score3/3
Weight-16.65%
1M Return-0.14%
Is RCEL undervalued or overvalued?
  • RCEL scores 9.97/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.00% ROE, -67.06% net margin, -2.31 P/E ratio, -17.84 P/B ratio, and 18.83% earnings growth, these metrics solidify its Outperform investment rating.